{"groups":[{"description":"All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks","id":"FG000","title":"Pasireotide LAR"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Acute or progressive vision loss"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Uncontrolled diabetes mellitus"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"abnormal laboratory values"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"comment":"received at least 1 dose of study medication","type":"Full Analysis Set (FAS)"},{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"comment":"rec'd at least 1 dose of drug + 1 at least one post-BL safety assessment","type":"Safety Analysis Set"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Main Phase"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Administrative problems"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"comment":"received at least 1 dose of study drug","type":"Full Analysis Set (FAS)"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"comment":"rec'd at least 1 dose of drug + 1 at least one post-BL safety assessment","type":"Safety Analysis Set"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Extension Phase"}],"preAssignmentDetails":"Twenty seven patients were screened and 21 met eligibility requirements."}